A new engineered gene-editing system, proven in bacteria and showing promise for use in plants, animals and humans, addresses ...

Caribou Biosciences is stopping work on its two remaining cancer cell therapies and exploring strategic alternatives for the ...

In the latest close session, CRISPR Therapeutics AG (CRSP) was down 5.82% at $54.00. The stock trailed the S&P 500, which registered a daily gain of 0.58%. Meanwhile, the Dow experienced a rise of ...

A patient in Germany has been successfully treated with a drug based on CRISPR gene-editing technology for the first time since the therapy was approved, the Charité medical school and hospital in ...

The Berkeley gene-editing company will wind down its lymphoma and myeloma studies and explore a potential sale.

Roughly three-quarters of the human genome is transcribed into RNA, yet fewer than five percent of those sequences carry ...

CRISPR diagnostics merge point-of-care and molecular testing, enabling rapid, low-cost detection, frontline protocol disruption and emerging investment opportunities.Dublin, Oct. 02, 2026 (GLOBE ...

Algen Biotechnologies, a precision therapeutics company pioneering the use of advanced CRISPR and AI to close the gap between promising experimental data and real patient outcomes, today announced it ...

Despite having an allogeneic cell therapy prospect that’s ready for late-stage testing in lymphoma, Caribou couldn’t secure ...

IntroductionCRISPR-Cas has fundamentally transformed the landscape of genetic manipulation in life sciences. This technology, which recognizes, cuts, and edits specific DNA sequences, is utilized in a ...

A Minneapolis food-technology company has begun harvesting the first outdoor, commercial-scale planting of peanuts ...